A rational approach for selection of optimal covariate-based dosing strategies

被引:14
作者
Jönsson, S [1 ]
Karlsson, MO [1 ]
机构
[1] Uppsala Univ, Div Pharmacokinet & Drug Therapy, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden
关键词
D O I
10.1067/mcp.2003.2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. At present, there is no rational approach for choosing a dosing strategy for individualization based on a covariate. An approach to use in establishment of an a priori dosing strategy for individualization is presented. Factors influencing the choice of such a dosing strategy are identified. Methods. The approach requires definition of the following: target variable, seriousness of deviations from the target (ie, risk function), population model, covariate distributions, and constraints. Minimizing the total risk yields an optimal dosing strategy, estimated as dose sizes for different subpopulations and covariate cutoff values at which doses are incremented or decremented. The method was illustrated with the use of simulated and real drug examples for the situation in which clearance is related to creatinine clearance. Results. The estimated optimal cutoff(s) paralleled the median creatinine clearance in the population. The extent of variability in clearance explained by creatinine clearance Was the main factor influencing the optimal ratios between adjacent dose sizes. An optimal dosing strategy was possible to estimate for the real drug. Conclusions: The method is simple to perform, although one difficulty lies in defining the target variable and risk function. Our results imply that commonly used constraints in dosing strategies based on renal function.(ie, dose ratio of 2 and predetermined cutoffs) are nonoptimal in the sense we propose. Because an optimal dosing strategy may not be practical to use, the therapeutic cost that would result with any constraint can be assessed by comparison of the outcome after the desired and the optimal strategy.
引用
收藏
页码:7 / 19
页数:13
相关论文
共 23 条
  • [1] DESIGN OF DOSAGE REGIMENS - A MULTIPLE MODEL STOCHASTIC-CONTROL APPROACH
    BAYARD, DS
    MILMAN, MH
    SCHUMITZKY, A
    [J]. INTERNATIONAL JOURNAL OF BIO-MEDICAL COMPUTING, 1994, 36 (1-2): : 103 - 115
  • [2] BEAL SL, 1998, NONMEM US GUIDES
  • [3] Practical treatment guide for dose individualisation in cancer chemotherapy
    Canal, P
    Chatelut, E
    Guichard, S
    [J]. DRUGS, 1998, 56 (06) : 1019 - 1038
  • [4] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [5] Modeling INR data to predict maintenance fluindione dosage
    Comets, E
    Mentre, F
    Pousset, F
    Diquet, B
    Montalescot, G
    Ankri, A
    Mallet, A
    Lechat, P
    [J]. THERAPEUTIC DRUG MONITORING, 1998, 20 (06) : 631 - 639
  • [6] D'Argenio D.Z., 1988, BIOMED MEAS INFOR CO, V2, P115
  • [7] TARGETING THE SYSTEMIC EXPOSURE OF TENIPOSIDE IN THE POPULATION AND THE INDIVIDUAL USING A STOCHASTIC THERAPEUTIC OBJECTIVE
    DARGENIO, DZ
    RODMAN, JH
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (02): : 223 - 251
  • [8] *FASS, 1999, LAK SVER FORT HUM LA
  • [9] NETILMICIN IN THE NEONATE - POPULATION PHARMACOKINETIC ANALYSIS AND DOSING RECOMMENDATIONS
    FATTINGER, K
    VOZEH, S
    OLAFSSON, A
    VLCEK, J
    WENK, M
    FOLLATH, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (01) : 55 - 65
  • [10] POPULATION PHARMACOKINETICS OF QUINIDINE
    FATTINGER, K
    VOZEH, S
    HA, HR
    BORNER, M
    FOLLATH, F
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (03) : 279 - 286